News & Events

November 24, 2020

CARISMA THERAPEUTICS TO PRESENT AT UPCOMING VIRTUAL INVESTOR CONFERENCES IN DECEMBER

CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, the President & CEO, will present at two virtual investor conferences in December 2020. Piper Sandler 32nd Annual Virtual Healthcare Conference November 30, 2020- December 3, 2020 Presentations will be available for registered attendees via the Piper Sandler […]

Read More
November 9, 2020

CARISMA to Present New Data at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting

PHILADELPHIA, Nov. 9, 2020 /PRNewswire/ — CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced new preclinical findings accepted for presentation at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting (November 9 – 14, 2020). Click here for more information.

Read More
August 25, 2020

CARISMA Therapeutics Enters Into Scientific Research and Licensing Agreement With NYU Langone Health, Gains Exclusive Rights to Vpx Lentiviral Vector

PHILADELPHIA, Aug. 25, 2020 /PRNewswire/ — CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced it has entered into a scientific research and licensing agreement with Nathaniel R. Landau, PhD and NYU Langone Health through which CARISMA will attain exclusive rights to develop and commercialize their Vpx lentiviral vector globally for all indications. […]

Read More
July 27, 2020

CARISMA Therapeutics Announces FDA Clearance of IND Application for First-Ever Engineered Macrophage Immunotherapy

PHILADELPHIA, July 27, 2020 /PRNewswire/ — CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for the Company’s lead product candidate, CT-0508, an anti-human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-M). […]

Read More